This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

New Peer-reviewed Publication Offers Guidance For Integrating Gattex® (Teduglutide [rDNA Origin]) For Injection Into Management Of Short Bowel Syndrome

Stocks in this article: NPSP

The Journal of Parenteral and Enteral Nutrition recently published clinical considerations and best-practice recommendations for introducing Gattex ® (teduglutide [rDNA origin]) for injection into the management of short bowel syndrome (SBS). The recommendations conclude that integrating Gattex into a coordinated approach to treating SBS may result in more success in rehabilitating the intestine and weaning from parenteral nutrition (PN)/intravenous (IV) fluids in these patients.

Gattex is indicated for the treatment of adults with SBS who are dependent on parenteral support. Full prescribing information for Gattex is available at www.Gattex.com. The complete guidelines can be viewed at the Journal of Parenteral and Enteral Nutrition website by searching “teduglutide.”

The goal of intestinal rehabilitation is to enhance nutrient processing and absorptive capacity of the remaining gastrointestinal tract, allowing for maximum oral intake of nutrients and fluids. Until recently, the approaches for achieving this goal have been limited to dietary intervention, antidiarrheal and antisecretory medications, and surgical bowel reconstruction. The article considers the integration of Gattex, a targeted agent, in conjunction with best-practice recommendations, including strategies for PN/IV weaning and the importance of an integrated approach centering on specialized care.

“Teduglutide achieves intestinal adaptation as evidenced by significant reductions in PN/IV dependence or even complete weaning of this supportive care in some patients with short bowel syndrome,” said Douglas L. Seidner, MD, director of Vanderbilt Center for Human Nutrition at Vanderbilt Medical Center in Nashville and lead author. “Due to the complexities of short bowel syndrome and the need for individualized management strategies, patients should be referred to major centers with experience in short bowel syndrome, particularly during the early stages of teduglutide treatment.”

Prior to initiating therapy with Gattex, the authors suggest optimizing fluids, electrolytes, nutrients, and adjunctive medications. They also recommend establishing baseline parameters for monitoring purposes, particularly nutrient balance and liver function for those requiring long-term, home use of parenteral nutrition, or HPN. Pre-planning and communication between the various healthcare providers and the patient are strongly recommended to allow for a well-coordinated care plan. Further, the authors recommend that patients be referred to major centers with experience in intestinal rehabilitation and that Gattex prescribers adhere to the warnings and requirements for the specific population of patients described in the product’s label.

1 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,614.81 +215.14 1.31%
S&P 500 1,941.28 +37.27 1.96%
NASDAQ 4,419.4780 +103.4040 2.40%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs